However, as AURKA and NEDD9 are highly expressed in the left atrial tissue of AF patients, and Alisertib has been described to have no clinically relevant effects on cardiac repolarization or ECG parameters66, targeting NEDD9/AURKA/HDAC6 axis is attractive as a novel treatment for fibrosis in AF. The gene discussed is HDAC6; the disease is atrial fibrillation.